The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer.

Abstract:

BACKGROUND:The activity and synergy for the combination treatment of cisplatin and gemcitabine has been identified in a variety of human tumor cells, including ovarian cancer cells, and has been widely approved for the treatment of non-small cell lung cancer, pancreatic cancer and biliary tract cancer. As the gastrointestinal symptoms with cisplatin therapy are commonly considered to negatively affect the quality of life of patients more than those experienced with carboplatin therapy, carboplatin is generally preferred over cisplatin in combination therapy. This study evaluated the safety and efficacy of cisplatin plus gemcitabine in patients with recurrent ovarian cancer. METHODS:Patients with recurrent ovarian, peritoneal or fallopian tube cancer, who had failed with multiple other chemotherapy agents, including platinum, received cisplatin (30 mg/m(2)) plus gemcitabine (750 mg/m(2)) on days 1 and 8 of every 28 days for between 1 and 4 cycles. RESULTS:In total, 18 patients were treated with cisplatin and gemcitabine between 2006 and 2011. There were 1 complete and 5 partial responses, producing an overall response rate of 33.4 %. Median overall survival was 11.0 months. Grade 4 neutropenia and thrombocytopenia were seen in 11.1 and 22.2 % of patients, respectively. Non-hematological toxicity was less than Grade 1. CONCLUSIONS:Non-hematological toxicity with combined cisplatin and gemcitabine therapy was considered tolerable and did not impede patient quality of life. However, this drug combination should be monitored for hematologic toxicity.

journal_name

Int J Clin Oncol

authors

Tomita Y,Saito T,Okadome M,Eto T,Ariyoshi K,Shimamoto K

doi

10.1007/s10147-013-0599-5

subject

Has Abstract

pub_date

2014-08-01 00:00:00

pages

662-6

issue

4

eissn

1341-9625

issn

1437-7772

journal_volume

19

pub_type

杂志文章
  • The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen.

    abstract:BACKGROUND:Our aim was to study the efficacy and safety of combination chemotherapy with gemcitabine plus cisplatin (GC) for patients with advanced urothelial carcinoma (UC) after failure of methotrexate, vinblastin, adriamycin, and cisplatin (M-VAC) chemotherapy. METHODS:We studied a total of 33 patients with advance...

    journal_title:International journal of clinical oncology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10147-011-0188-4

    authors: Gondo T,Ohori M,Hamada R,Tanaka A,Satake N,Takeuchi H,Nakashima J,Hatano T,Tachibana M

    更新日期:2011-08-01 00:00:00

  • External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model.

    abstract:BACKGROUND:We conducted a study to validate the influence of the systemic immune-inflammation index (SII) on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) and to verify whether the implementation of the SII in place of neutrophil and platelet counts within the International Metastatic Re...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10147-018-01390-x

    authors: Chrom P,Zolnierek J,Bodnar L,Stec R,Szczylik C

    更新日期:2019-05-01 00:00:00

  • Treatment choices and outcomes of non-metastatic hepatocellular carcinoma patients in relationship to neighborhood socioeconomic status: a population-based study.

    abstract:OBJECTIVE:To assess the impact of socioeconomic status (SES) on treatment choices and outcomes of hepatocellular carcinoma (HCC) patients treated with local therapies (ablation or surgery). METHODS:Surveillance, Epidemiology and End Results (SEER) specialized socioeconomic database was accessed. Cases with non-metasta...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-020-01616-x

    authors: Abdel-Rahman O

    更新日期:2020-05-01 00:00:00

  • Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study.

    abstract:BACKGROUND:Whether the administration of calcium (Ca) and magnesium (Mg) can reduce oxaliplatin-related neurotoxicity remains controversial. In addition, little is known about the effects of Ca/Mg on the blood level of platinum or objective tumor progression. PATIENTS AND METHODS:Patients receiving modified FOLFOX6 fo...

    journal_title:International journal of clinical oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/s10147-009-0015-3

    authors: Ishibashi K,Okada N,Miyazaki T,Sano M,Ishida H

    更新日期:2010-02-01 00:00:00

  • FDG-PET reflects tumor viability on SUV in colorectal cancer liver metastasis.

    abstract:BACKGROUND:Liver resection is the most effective procedure for colorectal cancer liver metastasis (CRLM); however, early recurrence is an important problem that affects the postoperative prognoses of patients with CRLM. We previously suggested a therapeutic algorithm for CRLM using fluorodeoxyglucose-positron emission ...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-019-01557-0

    authors: Watanabe A,Harimoto N,Yokobori T,Araki K,Kubo N,Igarashi T,Tsukagoshi M,Ishii N,Yamanaka T,Handa T,Oyama T,Higuchi T,Shirabe K

    更新日期:2020-02-01 00:00:00

  • Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer.

    abstract::The fourth edition of the Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer was published in 2015. The guidelines contain seven chapters and six flow charts. The major changes in this new edition are as follows-(1) the for...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章,实务指引

    doi:10.1007/s10147-016-0985-x

    authors: Komiyama S,Katabuchi H,Mikami M,Nagase S,Okamoto A,Ito K,Morishige K,Suzuki N,Kaneuchi M,Yaegashi N,Udagawa Y,Yoshikawa H

    更新日期:2016-06-01 00:00:00

  • Loco-regional failures in head and neck cancer: can they be effectively salvaged by nonsurgical therapeutic modalities?

    abstract:BACKGROUND:This retrospective study was carried out to ascertain the extent of efficacy of nonsurgical salvage modalities, mainly chemotherapy (CT) alone or chemoradiotherapy (CTRT), for loco-regional failures in head and neck cancer (HNC). METHODS:Between 1991 and 1999, 131 patients with HNC, mostly stages III and IV...

    journal_title:International journal of clinical oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/s101470300004

    authors: Datta NR,Nagar YS,Singh S,Naryan L

    更新日期:2003-02-01 00:00:00

  • Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation.

    abstract:BACKGROUND:It is still controversial whether axillary lymph node (ALN) dissection (ALND) can be omitted after negative sentinel lymph node (SLN) biopsy (SLNB) in breast cancer (BC) patients with clinically positive ALNs at presentation treated with neoadjuvant chemotherapy (NAC). The study aim was to analyze whether SL...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-012-0418-4

    authors: Takei H,Yoshida T,Kurosumi M,Inoue K,Matsumoto H,Hayashi Y,Higuchi T,Uchida S,Ninomiya J,Kubo K,Oba H,Nagai S,Tabei T

    更新日期:2013-06-01 00:00:00

  • A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.

    abstract:BACKGROUND:In Japan, chemotherapeutic agents that have been approved for the treatment of esophageal cancer include cisplatin, nedaplatin, 5-fluorouracil, vindesine, and docetaxel. We retrospectively investigated the efficacy and toxicity of a combination of nedaplatin plus vindesine, or docetaxel alone, for patients w...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-007-0738-y

    authors: Yamazaki K,Hironaka S,Boku N,Yasui H,Fukutomi A,Yoshino T,Onozawa Y,Hasuike N,Inui T,Yamaguchi Y,Ono H

    更新日期:2008-04-01 00:00:00

  • Association of atopic diseases and parvovirus B19 with acute lymphoblastic leukemia in childhood and adolescence in the northeast of Brazil.

    abstract:BACKGROUND:Several factors related to the immune system, such as a history of allergies and virus infections, may be associated with acute lymphoblastic leukemia (ALL). The purpose of this study was to analyze whether the presence of atopic diseases and previous infection with parvovirus B19 and Epstein-Barr virus (EBV...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-016-0988-7

    authors: da Conceição Nunes J,de Araujo GV,Viana MT,Sarinho ES

    更新日期:2016-10-01 00:00:00

  • Metastatic collecting duct carcinoma of the kidney responded to sunitinib.

    abstract::Collecting duct carcinoma (CDC) of the kidney is a rare and aggressive malignant tumor arising from the distal collecting tubules which has been shown to have a poor response to several kinds of systemic therapy. We present a case of metastatic CDC that responded favorably to a multiple tyrosine kinase inhibitor, suni...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-010-0116-z

    authors: Miyake H,Haraguchi T,Takenaka A,Fujisawa M

    更新日期:2011-04-01 00:00:00

  • A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen.

    abstract:BACKGROUND:The combination of a new oral dihydropyrimidine dehydrogenase-inhibitory fluoropyrimidine (S-1) and cisplatin (CDDP) is one of the most active chemotherapy regimens for gastric cancer. However, the optimum schedule for this combination has not yet been determined. This study was conducted to establish the ma...

    journal_title:International journal of clinical oncology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10147-004-0451-z

    authors: Sato Y,Kondo H,Honda K,Takahari D,Sumiyoshi T,Tsuji Y,Yoshizaki N,Niitsu Y

    更新日期:2005-02-01 00:00:00

  • Performance of outpatient regimen of S-1 in combination with fractional cisplatin for advanced or recurrent gastric cancers: a phase I study.

    abstract:BACKGROUND:We designed an outpatient regimen consisting of fractional cisplatin in combination with S-1, a novel oral fluoropyrimidine derivative for the treatment of recurrent or advanced gastric cancer and conducted a phase I study to determine the dose limiting toxicities (DLTs) and recommended dose (RD). METHODS:E...

    journal_title:International journal of clinical oncology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10147-005-0505-x

    authors: Shimoyama S,Imamura K,Hiki N,Yamaguchi H,Mafune K,Kaminishi M

    更新日期:2005-08-01 00:00:00

  • Set-up errors and planning target volume margins in head and neck cancer radiotherapy: a clinical study of image guidance with on-line cone-beam computed tomography.

    abstract:BACKGROUND:Set-up errors represent a source of uncertainty in head and neck (H&N) cancer radiotherapy. The present study evaluated set-up accuracy with the use of cone-beam computed tomography (CBCT) in order to establish the proper clinical target volume (CTV) to planning target volume (PTV) margins to be adopted. ME...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-012-0395-7

    authors: Dionisi F,Palazzi MF,Bracco F,Brambilla MG,Carbonini C,Asnaghi DD,Monti AF,Torresin A

    更新日期:2013-06-01 00:00:00

  • Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary.

    abstract:BACKGROUND:Recent studies have shown that somatic mutations in the AT-rich interactive domain 1A (SWI-like) gene (ARID1A) are the most common genetic changes in clear cell carcinoma of the ovary (CCC). A gene mutation of ARID1A was found in approximately half of CCC cases, and led to absence of the encoded protein and ...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-015-0811-x

    authors: Itamochi H,Oumi N,Oishi T,Shoji T,Fujiwara H,Sugiyama T,Suzuki M,Kigawa J,Harada T

    更新日期:2015-10-01 00:00:00

  • Distribution analysis of hydrogel spacer and evaluation of rectal dose reduction in Japanese prostate cancer patients undergoing stereotactic body radiation therapy.

    abstract:BACKGROUND:To report on our primary experience with the placement of a hydrogel spacer following stereotactic body radiation therapy (SBRT) in low- and intermediate-risk prostate cancer patients and assess its impact on dosimetry as well as acute toxicity. METHODS:A total of 70 patients treated with SBRT (total dose o...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-020-01855-y

    authors: Kobayashi H,Eriguchi T,Tanaka T,Ogata T,Ishida M,Nakajima Y,Kumabe A,Kosugi M

    更新日期:2021-01-07 00:00:00

  • Treatment strategies for neuroendocrine carcinoma of the upper digestive tract.

    abstract:BACKGROUND:Neuroendocrine carcinoma (NEC) of the esophagus and the stomach is aggressive. The purpose of this study was to determine the optimal therapeutic strategy. METHODS:Both clinicopathological factors and treatment results were examined in 34 patients with immunohistochemically diagnosed NEC of the upper gastro...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-020-01631-y

    authors: Morita M,Taguchi K,Kagawa M,Nakanoko T,Uehara H,Sugiyama M,Ota M,Ikebe M,Sugimachi K,Esaki T,Toh Y

    更新日期:2020-05-01 00:00:00

  • Comparisons of the impact of systematic uncertainties in patient setup and prostate motion on doses to the target among different plans for definitive external-beam radiotherapy for prostate cancer.

    abstract:BACKGROUND:We aimed to compare the impact of systematic uncertainties in patient setup and prostate motion on three different external-beam radiotherapy protocols for prostate cancer. METHODS:To simulate possible near-maximum systematic errors, the isocenter position was shifted to eight points with +/-1.65 SD of the ...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-007-0724-4

    authors: Zhu SY,Mizowaki T,Norihisa Y,Takayama K,Nagata Y,Hiraoka M

    更新日期:2008-02-01 00:00:00

  • Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil.

    abstract:BACKGROUND:This study was conducted to evaluate the prognostic significance of thymidylate synthase (TS) expression in the tumor tissue of patients with metastatic colorectal cancer (CRC) who received protracted venous infusions of 5-fluorouracil (5-FU). METHODS:We retrospectively analyzed the prognostic value of TS e...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-004-0425-1

    authors: Hosokawa A,Yamada Y,Shimada Y,Muro K,Hamaguchi T,Morita H,Araake M,Orita H,Shirao K

    更新日期:2004-10-01 00:00:00

  • Differences in histological features and PD-L1 expression between sporadic microsatellite instability and Lynch-syndrome-associated disease in Japanese patients with colorectal cancer.

    abstract:BACKGROUND:The field of immunotherapy has recently focused on cancers with microsatellite instability (MSI). These cancers include both Lynch-syndrome-associated tumors, which are caused by mismatch repair (MMR) germline mutations, and sporadic MSI tumors, which are mainly attributed to MLH1 promoter methylation. The p...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-018-1238-y

    authors: Yamada R,Yamaguchi T,Iijima T,Wakaume R,Takao M,Koizumi K,Hishima T,Horiguchi SI

    更新日期:2018-06-01 00:00:00

  • Multiple primary cancer: an experience at the Cancer Institute Hospital with special reference to colorectal cancer.

    abstract:BACKGROUND:Cancer patients are at high risk of developing a second cancer after the treatment of initial cancers. Understanding the characteristics of multiple primary cancer is important to establish an effective surveillance program for the early detection of second cancers. METHODS:We analyzed the cancer registry r...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-003-0322-z

    authors: Ueno M,Muto T,Oya M,Ota H,Azekura K,Yamaguchi T

    更新日期:2003-06-01 00:00:00

  • Health-related quality of life in Japanese patients with metastatic renal cell carcinoma treated with sunitinib.

    abstract:BACKGROUND:To analyze the impact of sunitinib treatment on health-related quality of life (HRQOL) in Japanese patients with metastatic renal cell carcinoma (mRCC). METHODS:This study prospectively included 90 consecutive patients with mRCC treated with sunitinib for at least 3 months. HRQOL in these patients was asses...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-011-0364-6

    authors: Miyake H,Harada K,Kusuda Y,Fujisawa M

    更新日期:2013-04-01 00:00:00

  • A case report of metastatic neuroendocrine carcinoma of the right adrenal gland successfully treated with chemotherapy and surgery.

    abstract::Poorly differentiated neuroendocrine carcinoma has a poor prognosis, especially when associated with distant metastasis. A 60-year-old man was admitted to a private hospital because of dyspnea at work in 2007. Computed tomography revealed lung infarction and a right adrenal tumor sized 12 cm in diameter that was tight...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-010-0051-z

    authors: Ochiai T,Komiyama S,Ikoma H,Kubota T,Nakanishi M,Ichikawa D,Kikuchi S,Fujiwara H,Sakakura C,Kokuba Y,Sonoyama T,Otsuji E

    更新日期:2010-08-01 00:00:00

  • Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer.

    abstract:BACKGROUND:No investigation of S-1 monotherapy in previously treated advanced non-small-cell lung cancer (NSCLC) patients has yet been reported. We conducted a retrospective study to evaluate the efficacy and tolerability of S-1 in patients with failure of second- or further-line chemotherapy. PATIENTS AND METHODS:The...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-010-0034-0

    authors: Ono A,Naito T,Murakami H,Takahashi T,Nakamura Y,Tsuya A,Kaira K,Igawa S,Shukuya T,Tamiya A,Kaira R,Endo M,Yamamoto N

    更新日期:2010-04-01 00:00:00

  • A prognostic parameter in advanced non-small cell lung cancer: the ratio of hemoglobin-to-red cell distribution width.

    abstract:BACKGROUND:This study aims to investigate the prognostic value of the ratio of hemoglobin-RDW (HRR) at diagnosis, in terms of overall survival (OS) and progression-free survival in patients with advanced non-small cell lung cancer (NSCLC). METHODS:Patients with metastatic NCCLC who attended two separate medical oncolo...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-019-01417-x

    authors: Bozkaya Y,Kurt B,Gürler F

    更新日期:2019-07-01 00:00:00

  • Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer.

    abstract:BACKGROUNDS:The presence of ≥5 circulating tumor cells (CTCs) in 7.5 ml blood is a poor prognostic marker in metastatic breast cancer (MBC). However, the role of human epidermal growth factor receptor 2 (HER2) status in CTCs is not known. METHODS:We prospectively assessed the prognostic value of this parameter for pat...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-011-0260-0

    authors: Hayashi N,Nakamura S,Tokuda Y,Shimoda Y,Yagata H,Yoshida A,Ota H,Hortobagyi GN,Cristofanilli M,Ueno NT

    更新日期:2012-04-01 00:00:00

  • Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index.

    abstract:BACKGROUND:Obese women with estrogen receptor (ER)-positive breast cancer may experience worse disease-free and overall survival. We hypothesize that this observation is due to intrinsically aggressive disease and that obesity will be associated with higher histologic grade and Ki67. METHODS:A sequential cohort of wom...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-014-0712-4

    authors: Santa-Maria CA,Yan J,Xie XJ,Euhus DM

    更新日期:2015-04-01 00:00:00

  • A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age.

    abstract:OBJECTIVES:We retrospectively analyzed the clinicopathological features and evaluated the prognostic indicators of recurrence in 132 patients with clear cell adenocarcinoma (CCC) of the ovary at reproductive age. PATIENTS AND METHODS:Between 1986 and 2011, as a regional population-based study, clinicopathological data...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-013-0645-3

    authors: Kajiyama H,Mizuno M,Shibata K,Umezu T,Suzuki S,Yamamoto E,Mitsui H,Sekiya R,Niimi K,Kawai M,Nagasaka T,Kikkawa F

    更新日期:2014-10-01 00:00:00

  • Phase II study of a new multidisciplinary therapy using once every 3 week carboplatin plus dose-dense weekly paclitaxel before and after radical hysterectomy for locally advanced cervical cancer.

    abstract:BACKGROUND:We proposed a novel treatment strategy, consisting of triweekly cisplatin plus dose-dense weekly paclitaxel before and after radical hysterectomy without adjuvant radiation therapy to treat locally advanced cervical cancer. However, cisplatin-related severe non-hematologic toxicities were frequent during thi...

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-020-01787-7

    authors: Nagao S,Yamamoto K,Oishi T,Yamaguchi S,Takehara K,Shimada M,Kigawa J

    更新日期:2021-01-01 00:00:00

  • Malignant change secondary to fibrous dysplasia.

    abstract:BACKGROUND:Malignant change in fibrous dysplasia (FD) is very rare. This study was carried out to establish some characteristic clinical information about this disorder. METHODS:Four cases with a malignant change in FD out of 128 cases with FD were surgically treated and followed up for a median period of 61.3 months....

    journal_title:International journal of clinical oncology

    pub_type: 杂志文章

    doi:10.1007/s10147-006-0559-4

    authors: Hoshi M,Matsumoto S,Manabe J,Tanizawa T,Shigemitsu T,Izawa N,Takeuchi K,Kawaguchi N

    更新日期:2006-06-01 00:00:00